{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T02:44:51Z","timestamp":1787021091023,"version":"build-2736575974"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,7,14]],"date-time":"2023-07-14T00:00:00Z","timestamp":1689292800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,7,14]],"date-time":"2023-07-14T00:00:00Z","timestamp":1689292800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Baxalta US Inc., a Takeda company, Lexington, MA, USA","award":["Baxalta US Inc., a Takeda company, Lexington, MA, USA"],"award-info":[{"award-number":["Baxalta US Inc., a Takeda company, Lexington, MA, USA"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Patient Rep Outcomes"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Congenital thrombotic thrombocytopenic purpura (cTTP) is an ultra-rare, life-threatening hereditary disorder that causes patients to experience significant morbidity and decreased health-related quality of life (HRQoL). A cTTP disease-specific patient-reported outcome (PRO) instrument that is reflective of patients\u2019 experiences with the disorder does not currently exist. The objective of this study was to evaluate and validate the psychometric properties of the Congenital Thrombotic Thrombocytopenic Purpura\u2013Patient Experience Questionnaire (cTTP-PEQ), developed using a literature review, interviews with expert clinicians, and qualitative concept elicitation and cognitive debriefing interviews.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This prospective, observational study (NCT03519672) was conducted with patients diagnosed with cTTP currently receiving treatment. Patients were enrolled through investigator sites and direct-to-patient recruitment. Individuals completed electronic self-administered PRO measures, including the cTTP-PEQ, at baseline and Day 14 (+\u2009up to 10\u00a0days). The cTTP-PEQ consisted of five multi-item domains (Pain\/Bruising, Cognitive Impairment, Visual Impairment, Mood, Treatment Burden) and three single-item domains (Fatigue, Headache, Activity Limitation), and assessed symptoms and impact of cTTP in the previous 24\u00a0h, 7 days, and 2 weeks. Convergent and discriminant validity were evaluated using Spearman\u2019s rank correlation coefficients. Known-groups validity was assessed between patient groups separated by Patient Global Impression of Severity (PGI-S; normal vs. mild\/moderate\/severe). Internal reliability was assessed using Cronbach\u2019s alpha. Test\u2013retest reliability was assessed using intraclass correlation coefficients (ICCs).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Thirty-six patients participated in this study. Convergent validity was confirmed with high-to-moderate correlations (\n                      <jats:italic>r<\/jats:italic>\n                      \u2009\u2265\u20090.4) for 12\/15 hypothesized relationships between pairs of domains and\/or total scores. Discriminant validity was confirmed with low correlations (\n                      <jats:italic>r<\/jats:italic>\n                      \u2009&lt;\u20090.3) observed for 5\/7 hypothesized relationships. Known-groups validity was confirmed with significant differences (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009\u2264\u20090.05) in mean cTTP-PEQ scores between the two PGI-S groups for most domains and items at both timepoints. Cronbach\u2019s alpha was 0.88 at baseline and 0.91 at Day 14, confirming internal consistency of the instrument. Test\u2013retest reliability was also confirmed with a high ICC (0.96).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This study validates the psychometric properties of the novel cTTP-PEQ for use in research and clinical practice to assess HRQoL among patients with cTTP. This instrument will be particularly useful when assessing cTTP disease burden and the impact of new treatments.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s41687-023-00592-w","type":"journal-article","created":{"date-parts":[[2023,7,14]],"date-time":"2023-07-14T07:02:25Z","timestamp":1689318145000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Psychometric evaluation of a patient-reported outcomes instrument for congenital thrombotic thrombocytopenic purpura"],"prefix":"10.1186","volume":"7","author":[{"given":"Abiola","family":"Oladapo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diane","family":"Ito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana Mar\u00eda","family":"Rodriguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Philpott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Krupnick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veleka","family":"Allen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Hibbard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Scully","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruce","family":"Ewenstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,7,14]]},"reference":[{"issue":"2","key":"592_CR1","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1016\/j.mcna.2016.09.010","volume":"101","author":"JJ Shatzel","year":"2017","unstructured":"Shatzel JJ, Taylor JA (2017) Syndromes of thrombotic microangiopathy. Med Clin North Am 101(2):395\u2013415","journal-title":"Med Clin North Am"},{"issue":"21","key":"592_CR2","doi-asserted-by":"publisher","first-page":"2836","DOI":"10.1182\/blood-2016-10-709857","volume":"129","author":"BS Joly","year":"2017","unstructured":"Joly BS, Coppo P, Veyradier A (2017) Thrombotic thrombocytopenic purpura. Blood 129(21):2836\u20132846","journal-title":"Blood"},{"issue":"2","key":"592_CR3","doi-asserted-by":"publisher","first-page":"138","DOI":"10.5482\/HAMO-13-04-0026","volume":"33","author":"M Mansouri Taleghani","year":"2013","unstructured":"Mansouri Taleghani M, von Krogh AS, Fujimura Y, George JN, Hrachovinov\u00e1 I, Kn\u00f6bl PN et al (2013) Hereditary thrombotic thrombocytopenic purpura and the hereditary TTP registry. Hamostaseologie 33(2):138\u2013143","journal-title":"Hamostaseologie"},{"key":"592_CR4","unstructured":"Orphanet (2020), June 03 Congenital thrombotic thrombocytopenic purpura\u00a0https:\/\/www.orpha.net\/consor\/cgi-bin\/Disease_Search.php?lng=EN&data_id=12422&Disease_Disease_Search_diseaseGroup=upshawschulman&Disease_Disease_Search_diseaseType=Pat&Disease(s)\/group%20of%20diseases=Congenital-thrombotic-thrombocytopenicpurpura&title=Congenital-thrombotic-thrombocytopenic-purpura&search=Disease_Search_Simple. Accessed 03 September 2020"},{"issue":"6855","key":"592_CR5","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1038\/35097008","volume":"413","author":"GG Levy","year":"2001","unstructured":"Levy GG, Nichols WC, Lian EC, Foroud T, McClintick JN, McGee BM et al (2001) Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura. Nature 413(6855):488\u2013494","journal-title":"Nature"},{"issue":"17","key":"592_CR6","doi-asserted-by":"publisher","first-page":"1452","DOI":"10.4045\/tidsskr.15.1272","volume":"136","author":"AS von Krogh","year":"2016","unstructured":"von Krogh AS, Waage A, Quist-Paulsen P (2016) Congenital thrombotic thrombocytopenic purpura. Tidsskr Nor Laegeforen 136(17):1452\u20131457","journal-title":"Tidsskr Nor Laegeforen"},{"issue":"5","key":"592_CR7","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1111\/j.1365-2141.2008.07276.x","volume":"142","author":"M Scully","year":"2008","unstructured":"Scully M, Yarranton H, Liesner R, Cavenagh J, Hunt B, Benjamin S et al (2008) Regional UK TTP registry: correlation with laboratory ADAMTS 13 analysis and clinical features. Br J Haematol 142(5):819\u2013826","journal-title":"Br J Haematol"},{"issue":"5","key":"592_CR8","doi-asserted-by":"publisher","first-page":"e237","DOI":"10.1016\/S2352-3026(16)30018-7","volume":"3","author":"E Mariotte","year":"2016","unstructured":"Mariotte E, Azoulay E, Galicier L, Rondeau E, Zouiti F, Boisseau P et al (2016) Epidemiology and pathophysiology of adulthood-onset thrombotic microangiopathy with severe ADAMTS13 deficiency (thrombotic thrombocytopenic purpura): a cross-sectional analysis of the french national registry for thrombotic microangiopathy. Lancet Haematol 3(5):e237\u2013245","journal-title":"Lancet Haematol"},{"issue":"15","key":"592_CR9","doi-asserted-by":"publisher","first-page":"1644","DOI":"10.1182\/blood-2018-11-884700","volume":"133","author":"F Alwan","year":"2019","unstructured":"Alwan F, Vendramin C, Liesner R, Clark A, Lester W, Dutt T et al (2019) Characterization and treatment of congenital thrombotic thrombocytopenic purpura. Blood 133(15):1644\u20131651","journal-title":"Blood"},{"issue":"1","key":"592_CR10","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1002\/rth2.12066","volume":"2","author":"C Masias","year":"2018","unstructured":"Masias C, Cataland SR (2018) Novel therapies in thrombotic thrombocytopenic purpura. Res Pract Thromb Haemost 2(1):19\u201326","journal-title":"Res Pract Thromb Haemost"},{"issue":"10","key":"592_CR11","doi-asserted-by":"publisher","first-page":"2107","DOI":"10.3324\/haematol.2019.216796","volume":"104","author":"HA van Dorland","year":"2019","unstructured":"van Dorland HA, Taleghani MM, Sakai K, Friedman KD, George JN, Hrachovinova I et al (2019) The International Hereditary Thrombotic Thrombocytopenic Purpura Registry: key findings at enrollment until 2017. Haematologica 104(10):2107\u20132115","journal-title":"Haematologica"},{"issue":"5","key":"592_CR12","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1007\/s40271-019-00365-y","volume":"12","author":"AO Oladapo","year":"2019","unstructured":"Oladapo AO, Ito D, Hibbard C, Bean SE, Krupnick RN, Ewenstein BM (2019) Patient experience with congenital (hereditary) thrombotic thrombocytopenic purpura: a conceptual framework of symptoms and impacts. Patient 12(5):503\u2013512","journal-title":"Patient"},{"key":"592_CR13","first-page":"15","volume":"5","author":"P Blombery","year":"2014","unstructured":"Blombery P, Scully M (2014) Management of thrombotic thrombocytopenic purpura: current perspectives. J Blood Med 5:15\u201323","journal-title":"J Blood Med"},{"issue":"4","key":"592_CR14","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1055\/s-0034-1376883","volume":"40","author":"P Kn\u00f6bl","year":"2014","unstructured":"Kn\u00f6bl P (2014) Inherited and acquired thrombotic thrombocytopenic purpura (TTP) in adults. Semin Thromb Hemost 40(4):493\u2013502","journal-title":"Semin Thromb Hemost"},{"issue":"8","key":"592_CR15","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1002\/ajh.24060","volume":"90","author":"B Han","year":"2015","unstructured":"Han B, Page EE, Stewart LM, Deford CC, Scott JG, Schwartz LH et al (2015) Depression and cognitive impairment following recovery from thrombotic thrombocytopenic purpura. Am J Hematol 90(8):709\u2013714","journal-title":"Am J Hematol"},{"issue":"10","key":"592_CR16","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1002\/ajh.23527","volume":"88","author":"F Peyvandi","year":"2013","unstructured":"Peyvandi F, Mannucci PM, Valsecchi C, Pontiggia S, Farina C, Retzios AD (2013) ADAMTS13 content in plasma-derived factor VIII\/von willebrand factor concentrates. Am J Hematol 88(10):895\u2013898","journal-title":"Am J Hematol"},{"issue":"Suppl 1","key":"592_CR17","doi-asserted-by":"publisher","first-page":"65S","DOI":"10.1111\/j.1537-2995.2012.03663.x","volume":"52","author":"S Pandey","year":"2012","unstructured":"Pandey S, Vyas GN (2012) Adverse effects of plasma transfusion. Transfusion 52(Suppl 1):65S\u201379S","journal-title":"Transfusion"},{"issue":"2","key":"592_CR18","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1111\/vox.12090","volume":"106","author":"S McGuckin","year":"2014","unstructured":"McGuckin S, Westwood JP, Webster H, Collier D, Leverett D, Scully M (2014) Characterization of the complications associated with plasma exchange for thrombotic thrombocytopaenic purpura and related thrombotic microangiopathic anaemias: a single institution experience. Vox Sang 106(2):161\u2013166","journal-title":"Vox Sang"},{"issue":"1","key":"592_CR19","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1111\/j.1537-2995.2008.01938.x","volume":"49","author":"QF Lewis","year":"2009","unstructured":"Lewis QF, Lanneau MS, Mathias SD, Terrell DR, Vesely SK, George JN (2009) Long-term deficits in health-related quality of life after recovery from thrombotic thrombocytopenic purpura. Transfusion 49(1):118\u2013124","journal-title":"Transfusion"},{"issue":"9","key":"592_CR20","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.1007\/s00277-015-2411-2","volume":"94","author":"JN Saultz","year":"2015","unstructured":"Saultz JN, Wu HM, Cataland S (2015) Headache prevalence following recovery from TTP and aHUS. Ann Hematol 94(9):1473\u20131476","journal-title":"Ann Hematol"},{"issue":"6","key":"592_CR21","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1111\/j.1365-2516.2005.01144.x","volume":"11","author":"E Remor","year":"2005","unstructured":"Remor E, Arranz P, Quintana M, Villar A, Jim\u00e9nez-Yuste V, Diaz JL, Hemofilia-QoL Project Group et al (2005) Psychometric field study of the new haemophilia quality of life questionnaire for adults: the \u2018Hemofilia-QoL\u2019. Haemophilia 11(6):603\u2013610","journal-title":"Haemophilia"},{"issue":"Suppl 1","key":"592_CR22","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1111\/j.1355-0691.2004.00875.x","volume":"10","author":"S von Mackensen","year":"2004","unstructured":"von Mackensen S, Bullinger M, Haemo-QoL Group (2004) Development and testing of an instrument to assess the quality of life of children with Haemophilia in Europe (Haemo-QoL). Haemophilia 10(Suppl 1):17\u201325","journal-title":"Haemophilia"},{"issue":"8","key":"592_CR23","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1016\/j.jval.2011.06.013","volume":"14","author":"DL Patrick","year":"2011","unstructured":"Patrick DL, Burke LB, Gwaltney CJ, Leidy NK, Martin ML, Molsen E et al (2011) Content validity\u2013establishing and reporting the evidence in newly developed patient-reported outcomes (PRO) instruments for medical product evaluation: ISPOR PRO Good Research Practices Task Force report: part 2\u2013assessing respondent understanding. Value Health 14(8):978\u2013988","journal-title":"Value Health"},{"issue":"1","key":"592_CR24","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.jmpt.2003.11.003","volume":"27","author":"H Hurst","year":"2004","unstructured":"Hurst H, Bolton J (2004) Assessing the clinical significance of change scores recorded on subjective outcome measures. J Manipulative Physiol Ther 27(1):26\u201335","journal-title":"J Manipulative Physiol Ther"},{"issue":"11","key":"592_CR25","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1016\/j.jclinepi.2010.04.011","volume":"63","author":"D Cella","year":"2010","unstructured":"Cella D, Riley W, Stone A, Rothrock N, Reeve B, Yount S et al (2010) The patient-reported outcomes Measurement Information System (PROMIS) developed and tested its first wave of adult self-reported health outcome item banks: 2005\u20132008. J Clin Epidemiol 63(11):1179\u20131194","journal-title":"J Clin Epidemiol"},{"issue":"8","key":"592_CR26","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1023\/A:1026119331193","volume":"12","author":"M Kosinski","year":"2003","unstructured":"Kosinski M, Bayliss MS, Bjorner JB, Ware JE Jr, Garber WH, Batenhorst A et al (2003) A six-item short-form survey for measuring headache impact: the HIT-6. Qual Life Res 12(8):963\u2013974","journal-title":"Qual Life Res"},{"issue":"12","key":"592_CR27","doi-asserted-by":"publisher","first-page":"2062","DOI":"10.1111\/j.1538-7836.2008.03182.x","volume":"6","author":"M Bowman","year":"2008","unstructured":"Bowman M, Mundell G, Grabell J, Hopman WM, Rapson D, Lillicrap D et al (2008) Generation and validation of the condensed MCMDM-1VWD bleeding questionnaire for von Willebrand disease. J Thromb Haemost 6(12):2062\u20132066","journal-title":"J Thromb Haemost"},{"key":"592_CR28","first-page":"99","volume":"4","author":"M Sullivan","year":"1990","unstructured":"Sullivan M, Edgley K, DeHousx E (1990) A survey of multiple sclerosis, part 1: perceived cognitive problems and compensatory strategy use. Can J Rehabil 4:99\u2013105","journal-title":"Can J Rehabil"},{"issue":"7","key":"592_CR29","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1001\/archopht.119.7.1050","volume":"119","author":"CM Mangione","year":"2001","unstructured":"Mangione CM, Lee PP, Gutierrez PR, Spritzer K, Berry S, Hays RD, National Eye Institute Visual Function Questionnaire Field Test Investigators (2001) Development of the 25-item National Eye Institute visual function questionnaire. Arch Ophthalmol 119(7):1050\u20131058","journal-title":"Arch Ophthalmol"},{"issue":"5","key":"592_CR30","doi-asserted-by":"publisher","first-page":"353","DOI":"10.2165\/00019053-199304050-00006","volume":"4","author":"MC Reilly","year":"1993","unstructured":"Reilly MC, Zbrozek AS, Dukes EM (1993) The validity and reproducibility of a work productivity and activity impairment instrument. PharmacoEconomics 4(5):353\u2013365","journal-title":"PharmacoEconomics"},{"issue":"1","key":"592_CR31","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1067\/mob.2003.379","volume":"189","author":"I Yalcin","year":"2003","unstructured":"Yalcin I, Bump RC (2003) Validation of two global impression questionnaires for incontinence. Am J Obstet Gynecol 189(1):98\u2013101","journal-title":"Am J Obstet Gynecol"},{"issue":"1","key":"592_CR32","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1037\/0033-2909.112.1.155","volume":"112","author":"J Cohen","year":"1992","unstructured":"Cohen J (1992) A power primer. Psychol Bull 112(1):155\u2013159","journal-title":"Psychol Bull"},{"issue":"12","key":"592_CR33","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.1097\/00005650-199012000-00003","volume":"28","author":"AB Bindman","year":"1990","unstructured":"Bindman AB, Keane D, Lurie N (1990) Measuring health changes among severely ill patients. The floor phenomenon. Med Care 28(12):1142\u20131152","journal-title":"Med Care"}],"container-title":["Journal of Patient-Reported Outcomes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41687-023-00592-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s41687-023-00592-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41687-023-00592-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,14]],"date-time":"2023-07-14T18:01:49Z","timestamp":1689357709000},"score":1,"resource":{"primary":{"URL":"https:\/\/jpro.springeropen.com\/articles\/10.1186\/s41687-023-00592-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,14]]},"references-count":33,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["592"],"URL":"https:\/\/doi.org\/10.1186\/s41687-023-00592-w","relation":{},"ISSN":["2509-8020"],"issn-type":[{"value":"2509-8020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,14]]},"assertion":[{"value":"8 December 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 May 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 July 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"AO and DI are former employees of Baxalta US Inc., a Takeda company. CH and BE are employees of Takeda Development Center Americas, Inc. AMR, SP, RK, and VA are employees of IQVIA (formerly QuintilesIMS), a global provider of healthcare information and contract research services. MS has received speaker fees and advisory board honoraria from Takeda and research grants from Baxalta, a Takeda company, and Shire, a Takeda company.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The study was reviewed and approved by a central institutional review board in the US (Western IRB) and by the Health Research Authority and Health and Care Research Wales and the East Midlands\u2013Derby Research Ethics Committee in the UK. All patients provided informed consent and legally authorized representatives of participating adolescents provided informed consent on the adolescent\u2019s behalf.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}],"article-number":"68"}}